PURPOSE: In vivo studies have focused on the latter stages of the bone metastatic process (osteolysis), whereas little is known about earlier events, e.g., arrival, localization, and initial colonization. Defining these initial steps may potentially identify the critical points susceptible to therapeutic intervention. EXPERIMENTAL DESIGN: MDA-MB-435 human breast cancer cells engineered with green fluorescent protein were injected into the cardiac left ventricle of athymic mice. Femurs were analyzed by fluorescence microscopy, immunohistochemistry, real-time PCR, flow cytometry, and histomorphometry at times ranging from 1 hour to 6 weeks. RESULTS: Single cells were found in distal metaphyses at 1 hour postinjection and remained as single cells up to 72 hours. Diaphyseal arrest occurred rarely and few cells remained there after 24 hours. At 1 week, numerous foci (2-10 cells) were observed, mostly adjacent to osteoblast-like cells. By 2 weeks, fewer but larger foci (> or =50 cells) were seen. Most bones had a single large mass at 4 weeks (originating from a colony or coalescing foci) which extended into the diaphysis by 4 to 6 weeks. Little change (<20%) in osteoblast or osteoclast numbers was observed at 2 weeks, but at 4 to 6 weeks, osteoblasts were dramatically reduced (8% of control), whereas osteoclasts were reduced modestly (to approximately 60% of control). CONCLUSIONS: Early arrest in metaphysis and minimal retention in diaphysis highlight the importance of the local milieu in determining metastatic potential. These results extend the Seed and Soil hypothesis by demonstrating both intertissue and intratissue differences governing metastatic location. Ours is the first in vivo evidence that tumor cells influence not only osteoclasts, as widely believed, but also eliminate functional osteoblasts, thereby restructuring the bone microenvironment to favor osteolysis. The data may also explain why patients receiving bisphosphonates fail to heal bone despite inhibiting resorption, implying that concurrent strategies that restore osteoblast function are needed to effectively treat osteolytic bone metastases.
PURPOSE: In vivo studies have focused on the latter stages of the bone metastatic process (osteolysis), whereas little is known about earlier events, e.g., arrival, localization, and initial colonization. Defining these initial steps may potentially identify the critical points susceptible to therapeutic intervention. EXPERIMENTAL DESIGN: MDA-MB-435 humanbreast cancer cells engineered with green fluorescent protein were injected into the cardiac left ventricle of athymic mice. Femurs were analyzed by fluorescence microscopy, immunohistochemistry, real-time PCR, flow cytometry, and histomorphometry at times ranging from 1 hour to 6 weeks. RESULTS: Single cells were found in distal metaphyses at 1 hour postinjection and remained as single cells up to 72 hours. Diaphyseal arrest occurred rarely and few cells remained there after 24 hours. At 1 week, numerous foci (2-10 cells) were observed, mostly adjacent to osteoblast-like cells. By 2 weeks, fewer but larger foci (> or =50 cells) were seen. Most bones had a single large mass at 4 weeks (originating from a colony or coalescing foci) which extended into the diaphysis by 4 to 6 weeks. Little change (<20%) in osteoblast or osteoclast numbers was observed at 2 weeks, but at 4 to 6 weeks, osteoblasts were dramatically reduced (8% of control), whereas osteoclasts were reduced modestly (to approximately 60% of control). CONCLUSIONS: Early arrest in metaphysis and minimal retention in diaphysis highlight the importance of the local milieu in determining metastatic potential. These results extend the Seed and Soil hypothesis by demonstrating both intertissue and intratissue differences governing metastatic location. Ours is the first in vivo evidence that tumor cells influence not only osteoclasts, as widely believed, but also eliminate functional osteoblasts, thereby restructuring the bone microenvironment to favor osteolysis. The data may also explain why patients receiving bisphosphonates fail to heal bone despite inhibiting resorption, implying that concurrent strategies that restore osteoblast function are needed to effectively treat osteolytic bone metastases.
Authors: M Yang; E Baranov; P Jiang; F X Sun; X M Li; L Li; S Hasegawa; M Bouvet; M Al-Tuwaijri; T Chishima; H Shimada; A R Moossa; S Penman; R M Hoffman Journal: Proc Natl Acad Sci U S A Date: 2000-02-01 Impact factor: 11.205
Authors: Vahid Entezari; Pamela A Basto; Vartan Vartanians; David Zurakowski; Brian D Snyder; Ara Nazarian Journal: J Biomech Date: 2011-02-03 Impact factor: 2.712
Authors: Christopher P Geffre; Erika Pond; Gerald D Pond; Isis C Sroka; Jaime M Gard; Bethany A Skovan; William E Meek; Terry H Landowski; Raymond B Nagle; Anne E Cress Journal: Am J Transl Res Date: 2015-02-15 Impact factor: 4.060
Authors: Karen M Bussard; Noriaki Okita; Neil Sharkey; Thomas Neuberger; Andrew Webb; Andrea M Mastro Journal: Clin Exp Metastasis Date: 2010-05-06 Impact factor: 5.150
Authors: Linette Castillo-Pichardo; Michelle M Martínez-Montemayor; Joel E Martínez; Kristin M Wall; Luis A Cubano; Suranganie Dharmawardhane Journal: Clin Exp Metastasis Date: 2009-03-18 Impact factor: 5.150
Authors: Xin Lu; Qiongqing Wang; Guohong Hu; Catherine Van Poznak; Martin Fleisher; Michael Reiss; Joan Massagué; Yibin Kang Journal: Genes Dev Date: 2009-07-16 Impact factor: 11.361
Authors: Alla Bondareva; Charlene M Downey; Fabio Ayres; Wei Liu; Steven K Boyd; Benedikt Hallgrimsson; Frank R Jirik Journal: PLoS One Date: 2009-05-19 Impact factor: 3.240